Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIF1-alpha-specific siRNA
- Development stage
- Unknown
- Lead developer
- University of Nottingham
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Parenteral
01
Overview
HIF1-alpha-specific siRNA is a type of small interfering RNA (siRNA) designed to selectively silence the expression of the Hypoxia-inducible factor 1-alpha (HIF1A) gene. HIF1-alpha is a critical transcription factor that regulates the cellular response to hypoxia, a condition frequently found in the microenvironment of solid tumors like glioblastoma multiforme (GBM). By facilitating the degradation of HIF1A mRNA through the RNA-induced silencing complex (RISC), this siRNA reduces the synthesis of HIF1-alpha protein. This inhibition leads to the downregulation of various downstream targets involved in tumor progression, including those related to angiogenesis, metabolic reprogramming, and the maintenance of cancer stem cell populations (e.g., CD133). In research settings, it is utilized to investigate the role of hypoxia in tumor resistance and to evaluate the potential of HIF1-alpha as a therapeutic target.
- Other names
- HIF1A siRNAHIF-1A siRNAHIF 1A siRNAsiRNA targeting Hypoxia-inducible factor 1-alpha
02
Targets
HIF1A (Hypoxia-inducible factor 1-alpha)
Beyond the preview
Go deeper on HIF1-alpha-specific siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIF1-alpha-specific siRNA.